Holy Stone Healthcare participates in the Atlanta 2019 AACR Annual Meeting (2019/3/29-4/3) poster presentation. Dr. Eskouhie Tchaparian presented the company’s new drug, CA102N, targeting colorectal cancer.
Subject: Nonclinical safety evaluation of CA102N, a hyaluronic acid (HA) and nimesulide (Nim) conjugate, for colorectal cancer treatment
The American Association for Cancer Research (AACR) was founded in 1907 "to further the investigation and spread the knowledge of cancer." Today, the AACR accelerates progress toward the prevention and cure of cancer by promoting research, education, communication, and collaboration.
For more information about the AACR Annual Meeting 2019, please visit: